Photo from wikipedia
BACKGROUND Treatment of many diseases is a risk/benefit balancing act between positive and negative effects. As a surrogate parameter for treatment of diabetes mellitus type 2 (T2DM), Hemoglobin A1c (HbA1c)… Click to show full abstract
BACKGROUND Treatment of many diseases is a risk/benefit balancing act between positive and negative effects. As a surrogate parameter for treatment of diabetes mellitus type 2 (T2DM), Hemoglobin A1c (HbA1c) is used. Its target values are mostly based on findings in randomized clinical trials, which do not always reflect realworld medical practice. HbA1c target recommendations vary: A J-shaped curve for HbA1c has been discussed as results of meta-analyses (1), the possibility of “overtreatment”, especially in the elderly, has been suggested (2) and recent treatment guidelines have been loosened (3).
Journal Title: Value in Health
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!